- Home
- CERS vs PLX Comparison
CERS vs PLX Comparison
Compare CERS & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CERS | PLX |
|---|---|---|
| Founded | 1991 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 276.0M | 230.0M |
| IPO Year | 1996 | 1996 |
Fundamental Metrics
Financial Performance| Metric | CERS | PLX |
|---|---|---|
| Price | $1.88 | $2.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 1.6M | 1.4M |
| Earning Date | 05-22-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.27 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $51,326,000.00 | ★ $53,399,000.00 |
| Revenue This Year | $20.00 | $9.67 |
| Revenue Next Year | $9.60 | $23.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 30.68 | N/A |
| 52 Week Low | $1.12 | $1.34 |
| 52 Week High | $2.96 | $3.19 |
Technical Indicators
Market Signals| Indicator | CERS | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 34.95 | 52.42 |
| Support Level | $1.34 | $1.39 |
| Resistance Level | $2.26 | $3.11 |
| Average True Range (ATR) | 0.18 | 0.15 |
| MACD | -0.06 | -0.07 |
| Stochastic Oscillator | 2.93 | 37.85 |
Price Performance
Historical ComparisonAbout CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.